Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 17/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3076215 | 0.99 | HSD11B1 (0.56) | HSD11B1CNR1CNR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL3079492 | 0.90 | HSD11B1 (0.54) | HSD11B1CNR1CNR2ALDH1A1 | |
| SCHEMBL3062603 | 0.90 | HSD11B1 (0.55) | HSD11B1CNR1CNR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL3063351 | 0.89 | HSD11B1 (0.52) | HSD11B1CNR1CNR2 | |
| SCHEMBL3063126 | 0.88 | HSD11B1 (0.52) | HSD11B1CNR1CNR2 | |
| SCHEMBL3078565 | 0.86 | HSD11B1 (0.53) | HSD11B1CNR1CNR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL3069677 | 0.86 | HSD11B1 (0.50) | HSD11B1CNR1CNR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL3057271 | 0.84 | HSD11B1 (0.55) | HSD11B1CNR1CNR2ALDH1A1 | |
| SCHEMBL3082450 | 0.83 | HSD11B1 (0.54) | HSD11B1CNR1CNR2 | |
| SCHEMBL15016023 | 0.83 | HSD11B1 (0.44) | HSD11B1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2178845-B1 | INHIBITORS OF 11B-HYDROXYSTEROID DEHYDROGENASE | HOFFMANN LA ROCHE (CH) | 2013-06-19 | — | — | EP | claimed |
| US-7790711-B2 | Inhibitors of 11β-Hydroxysteroid Dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-09-07 | — | — | US | claimed |
| EP-2178845-A2 | INHIBITORS OF 11B-HYDROXYSTEROID DEHYDROGENASE | F. Hoffmann-Roche AG (CH) | 2010-04-28 | — | — | EP | claimed |
| US-20090023709-A1 | Inhibitors of 11B-Hyrdoxysteroid Dehydrogenase | GILLESPIE PAUL | 2009-01-22 | — | — | US | claimed |
| WO-2009010416-A2 | INHIBITORS OF 11B-HYDROXYSTEROID DEHYDROGENASE | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-22 | — | — | WO | claimed |
| US-8871208-B2 | 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof | ABBVIE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871208-B2 | 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof | ABBVIE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2178845-B1 | INHIBITORS OF 11B-HYDROXYSTEROID DEHYDROGENASE | HOFFMANN LA ROCHE (CH) | 2013-06-19 | — | — | EP | disclosed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| US-7790711-B2 | Inhibitors of 11β-Hydroxysteroid Dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790711-B2 | Inhibitors of 11β-Hydroxysteroid Dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790711-B2 | Inhibitors of 11β-Hydroxysteroid Dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2178845-A2 | INHIBITORS OF 11B-HYDROXYSTEROID DEHYDROGENASE | F. Hoffmann-Roche AG (CH) | 2010-04-28 | — | — | EP | disclosed |
| US-20090023709-A1 | Inhibitors of 11B-Hyrdoxysteroid Dehydrogenase | GILLESPIE PAUL | 2009-01-22 | — | — | US | disclosed |
| US-20090023709-A1 | Inhibitors of 11B-Hyrdoxysteroid Dehydrogenase | GILLESPIE PAUL | 2009-01-22 | — | — | US | disclosed |
| US-20090023709-A1 | Inhibitors of 11B-Hyrdoxysteroid Dehydrogenase | GILLESPIE PAUL | 2009-01-22 | — | — | US | disclosed |
| WO-2009010416-A2 | INHIBITORS OF 11B-HYDROXYSTEROID DEHYDROGENASE | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023709-A1 | Inhibitors of 11B-Hyrdoxysteroid Dehydrogenase | HSD17B1, HSD17B2, HSD11B1 | HSD11B1 3/4885CNR1 4361/4885CNR2 4415/4885 |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885CNR1 1935/4885CNR2 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.